ResMed reported solid QQ1 2026 results, underscoring durable demand for sleep and respiratory care devices alongside growing software-enabled services. Revenue of USD 1.336 billion marked a 9.19% year-over-year rise and 3.39% quarter-over-quarter expansion, supported by a robust gross margin of ~61.5% and a healthy operating margin around 33.4%. EBITDA stood at USD 494.5 million (margin ~37.0%), with net income of USD 348.5 million and EPS of USD 2.38 (diluted USD 2.37). The company generated substantial operating cash flow (USD 457.3 million) and delivered free cash flow of USD 414.4 million, reflecting disciplined capital allocation through modest capex and meaningful capital returns (dividends paid USD 87.8 million and share repurchases USD 150.0 million). ResMed maintains a strong balance sheet, ending QQ1 2026 with USD 1.38 billion in cash and a net cash position of approximately USD 537.5 million after considering approximately USD 846.4 million of debt. These fundamentals support ongoing investment in R&D and software-enabled services while preserving a flexible liquidity buffer to navigate external risks.